Authors
Laura Jiménez, Amanda Iglesias, Claudia A Almaraz, Meritxell López, Josep Muncunill, Aarne Fleischer, Maria Berman-Riu, Nuria Toledo-Pons, Ruth Engonga, Mar Mosteiro, Ines Escribano, Bartomeu Mestre, Borja G Cosio
Published in
Archivos de bronconeumologia. Nov 10, 2026. Epub Nov 10, 2026.
Abstract
Patients with severe uncontrolled asthma (SUA) and a T2 eosinophilic phenotype exhibit variable response to biologic therapy (BT). Currently, accurate biomarkers predicting this response are lacking. We aimed to explore whether microRNA (miRNA) and messenger RNA (mRNA) profiles in bronchial biopsies (BB) may help identify patients achieving a complete clinical response after 6 months of BT.
To explore whether BB miRNA and mRNA profiles may be associated with clinical response to BT in SUA population.
Thirty-four consecutive SUA patients with a T2 high phenotype were characterized and underwent bronchoscopy with BB before initiating anti-IL-5/5R BT. Clinical response was evaluated 6 months later. Both, miRNA and mRNA were extracted from BB, and their expression profiles were analyzed via microarrays. Gene Ontology and KEGG pathway analyses were performed to understand the biological functions and signaling pathways involved.
After BT, 64% showed complete clinical response, 18% patients were non-responders, and 18% obtained a partial response. Comparing non-responders vs. responders showed 35 differentially expressed mRNAs, and 8 miRNAs in BB samples. Integrated analysis of miRNA and mRNA data suggested that three key genes (FOXO1, ZBTB16 and OLFML3) may be involved in asthma pathogenesis.
Expression patterns between responders and non-responders to BT appeared to differ in BB of SUA patients, highlighting the involvement of multiple pathways related to airway inflammation and airway remodeling. Our results provide preliminary evidence suggesting that FOXO1, ZBTB16 and OLFML3 might be involved in the biological response to anti-IL-5/5R therapy.
PMID:
43009354
Bibliographic data and abstract were imported from PubMed on 11 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0